Search Results 671-680 of 1033 for Alopecia

  1. A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) - Mayo Clinic

    exception of alopecia, anorexia, nausea, vomiting, and fatigue) - Significant cardiovascular disease (such as New York Heart Association Class III or IV

  2. A Study to Test the Addition of berzosertib to Usual Radiation Treatment for Chemotherapy-Resistant Breast Cancer - Mayo Clinic

    Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia ...

  3. LC-MS/MS lowers diagnostic thresholds for androgen-producing tumors or pathological hyperandrogenism in women - Mayo Clinic

    52 (58%) women were diagnosed with polycystic ovary syndrome (PCOS). Women with APT were more likely to have male-pattern alopecia documented on physical ...

  4. A Study to Evaluate Genetic Testing in Guiding Treatment for Patients with Brain Metastases - Mayo Clinic

    ... alopecia or Grade 2 peripheral neuropathy prior to randomization. A washout period of at least 21 days is required between last chemotherapy dose and ...

  5. Trial of 225Ac-DOTATATE (RYZ101) Alone and with Pembrolizumab in Subjects with ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs (TRACY-1) - Mayo Clinic

    * Any toxicities from prior treatments that have not recovered to CTCAE Grade ≤1, except for alopecia. * Significant cardiovascular disease * Known brain ...

  6. Study Evaluating the Safety and Effectiveness of JCARH125 in Subjects with Relapsed and/or Refractory Multiple Myeloma (EVOLVE) - Mayo Clinic

    Recovery to ≤ Grade 1 or baseline of any non-hematological toxicities due to previous therapy, except alopecia and peripheral neuropathy. Females of ...

  7. Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer - Mayo Clinic

    ... alopecia and peripheral sensory neuropathy. - Subjects of childbearing potential agree to use two forms of medically approved contraception while taking the ...

  8. A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Participants With Prostate Cancer - Mayo Clinic

    ... alopecia or peripheral neuropathy AND have a washout period from last dose of prior systemic or radiation therapy as follows: Patients must discontinue ...

  9. Laser resurfacing - Doctors & Departments - Mayo Clinic

    ... Alopecia areata, Oral ulcerative condition, Facial volume loss, Vulvar disorder. Show more areas of focus for Alison J. Bruce, M.B., Ch.B.

  10. Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

    Resolution of all acute toxic effects of prior induction anti-HER2-based chemotherapy regimen to NCI CTCAE version 4.0 Grade ≤1 (except alopecia or other ...